{
    "clinical_study": {
        "@rank": "45413", 
        "arm_group": [
            {
                "arm_group_label": "IX-01 Capsule while Fasting", 
                "arm_group_type": "Experimental", 
                "description": "Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods"
            }, 
            {
                "arm_group_label": "IX-01 Aqueous Dispersion while Fasting", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods"
            }, 
            {
                "arm_group_label": "IX-01 Capsule after Food", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the absorption and blood levels of IX-01 when given\n      as a capsule compared to liquid form, and how food affects the absorption in healthy men."
        }, 
        "brief_title": "Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Participants", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A body mass index (Quetelet index) in the range 18-30 kilograms/meters squared\n             (kg/m2)\n\n          -  Body Mass Index = weight [kg] divided by (height [m])2\n\n          -  Total body weight greater than (>)50 kg at screening\n\n          -  Ability to communicate satisfactorily with the investigator and to participate in,\n             and comply with the requirements of, the entire trial\n\n          -  Participants and their partners must be willing to use adequate forms of\n             contraception and to comply with the contraception requirements during the trial and\n             for 4 months after the last dose of medication\n\n          -  Willingness to give written consent to have data entered into The Over Volunteering\n             Prevention System\n\n        Exclusion Criteria:\n\n          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at\n             the pre-trial screening assessment, including:\n\n               -  Lipid and/or liver function test results >1.25 x Upper Limit of Normal (ULN) or\n                  other clinical laboratory blood biochemistry test results outside the normal\n                  reference range unless discussed and approved by sponsor\n\n               -  International normalised ratio (INR) of >1.2 or a platelet count < 150 x\n                  109/Liter\n\n               -  History of unexplained syncope\n\n               -  Family history of unexplained sudden death, or sudden death due to long QT\n                  syndrome\n\n               -  Fridericia Correction Formula (QTcF) interval >450 milliseconds (msec) at\n                  screening\n\n               -  Bundle branch block and other conduction abnormalities, other than mild first\n                  degree atrio-ventricular block\n\n               -  Irregular rhythms other than sinus arrhythmia or occasional supraventricular\n                  ectopic beats\n\n               -  T-wave configuration of insufficient quality for determination of QT interval,\n                  as assessed by the investigator\n\n          -  Presence of acute or chronic illness or history of chronic illness sufficient to\n             invalidate participation in the trial\n\n          -  Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory,\n             haematological, renal or neurological function, diabetes mellitus, coronary heart\n             disease, or history of any psychotic mental illness\n\n          -  Surgery (for example (e.g.) stomach bypass) or medical condition that might affect\n             absorption, metabolism or elimination of medicines\n\n          -  Any skin condition, abnormality of the lumbar spine, medical or surgical condition\n             that would preclude lumbar puncture (e.g. coagulopathy, local or systemic infection,\n             left ventricular outflow obstruction, aortic stenosis, previous back surgery)\n\n          -  Presence or history of severe adverse reaction to any drug\n\n          -  Use of any prescription or over-the-counter medicine during the 14 days before the\n             first dose of trial medication, or intention to use any medicine during the trial,\n             with the exception of short courses of medication considered by the investigator not\n             to interfere with the safety of the participant or the integrity of the trial data\n             (such as acetaminophen (paracetamol))\n\n          -  Current use of any herbal remedy or nutritional supplement, or intention to use any\n             such product during the study\n\n          -  Participation in another clinical trial of a new chemical entity or a prescription\n             medicine within the previous 3 months.\n\n          -  Previous participation in this trial or any other clinical trial of an oxytocin\n             receptor antagonist\n\n          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of\n             alcohol weekly or more than 5 cigarettes daily\n\n          -  Blood pressure and heart rate in supine position at the screening examination outside\n             the ranges 100-130 millimeters of mercury (mm Hg) systolic, 60-90 mm Hg diastolic;\n             heart rate 50-100 beats/minute. Measurements must be made in duplicate, and all\n             values must fall within the acceptable ranges\n\n          -  Possibility that the participant will not cooperate with the requirements of the\n             protocol\n\n          -  Evidence of drug abuse on urine testing\n\n          -  Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1 (HIV1) or\n             Human Immunodeficiency Virus 2 (HIV2)\n\n          -  Loss of more than 400 mL blood during the 3 months before the trial, e.g. as a blood\n             donor\n\n          -  Objection by General Practitioner (GP), on medical grounds, to participant entering\n             trial\n\n          -  Employee of the investigator site or any company involved in sponsoring, organizing\n             or conducting the trial, or immediate family of the employee"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139826", 
            "org_study_id": "IX-0102"
        }, 
        "intervention": {
            "arm_group_label": [
                "IX-01 Capsule while Fasting", 
                "IX-01 Aqueous Dispersion while Fasting", 
                "IX-01 Capsule after Food"
            ], 
            "intervention_name": "IX-01", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "phone": "020-8963-4502"
            }, 
            "contact_backup": {
                "phone": "080-0783-8792"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Hammersmith Medicines Research"
            }, 
            "investigator": {
                "last_name": "Frans van den Berg, MBchB", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Single-dose, 3-way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Capsule Formulation Compared With the IX-01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Capsule Formulation, in Healthy Male Subjects", 
        "overall_contact": {
            "email": "Ixchelsis@Choruspharma.com", 
            "last_name": "Ixchelsis Limited"
        }, 
        "overall_official": {
            "affiliation": "Ixchelsis Limited", 
            "last_name": "Email: Ixchelsis@Choruspharma.com", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Relative Bioavailability (Frel) of a Capsule compared to a Liquid Formulation of IX-01 while Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve from Time 0 to Infinity", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post dose"
            }, 
            {
                "measure": "Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fasted State compared to the Fed State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve from Time 0 to Infinity", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post dose"
            }, 
            {
                "measure": "Relative Bioavailability (Frel) of a Capsule compared with a Liquid Formulation of IX-01 while Fasting, as calculated by a Ratio of Peak Plasma Concentrations", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post dose"
            }, 
            {
                "measure": "Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in a Fasted State compared to a Fed State, as calculated by a Ratio of Peak Plasma Concentrations", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post dose"
            }, 
            {
                "measure": "Area Under the Plasma Concentration Time Curve from Time 0 to Infinity, Following a Single Dose of IX-01", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 96 hours post dose"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of IX-01", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 96 hours post dose"
            }, 
            {
                "measure": "Time to Peak Plasma Concentration (Tmax) of IX-01", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post dose"
            }, 
            {
                "measure": "Elimination Half Life (t1/2) of IX-01", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post dose"
            }, 
            {
                "measure": "Elimination Rate Constant (Kel) of IX-01", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 96 hours post last dose"
            }, 
            {
                "measure": "Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Measurable Sample of IX-01", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to the time of the last measurable sample"
            }, 
            {
                "description": "Listed by time point of 1, 2, 4, 6 hours post dose", 
                "measure": "Concentration of IX-01 in Cerebrospinal Fluid (CSF) after a Single Dose of the Liquid Formulation of IX-01", 
                "safety_issue": "No", 
                "time_frame": "1, 2, 4 and 6 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with One or More Drug-Related Adverse Events (AEs) or any Serious AEs", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to study completion (approximately 6 weeks)"
        }, 
        "source": "Ixchelsis Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ixchelsis Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}